New drug cocktail shows promise for Tough-to-Treat myeloma

NCT ID NCT03590652

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested a combination of four drugs (daratumumab, ixazomib, pomalidomide, and dexamethasone) in 23 people with multiple myeloma that had come back or stopped responding to earlier treatments. The goal was to see how many patients' tumors shrank or disappeared. The study was stopped early, but the results help doctors understand if this powerful mix can control the disease for a while longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UCSD Moores Cancer Center

    La Jolla, California, 92093, United States

  • University of California, Davis

    Sacramento, California, 95817, United States

  • University of California, Los Angeles

    Los Angeles, California, 90024, United States

  • University of California, San Francisco

    San Francisco, California, 94115, United States